Targeting Ferroptosis Alleviates Pulmonary Arterial Hypertension, Insights from Transcriptomic and Experimental...

Area of Science:

• Cardiovascular Research
• Cell Biology
• Pulmonary Medicine

Background:

• Pulmonary arterial hypertension (PAH) involves pulmonary vascular remodeling due to endothelial cell injury.
• The precise mechanisms driving this injury and remodeling remain incompletely understood.

Purpose of the Study:

• To investigate the role of ferroptosis in the development of pulmonary arterial hypertension (PAH).
• To elucidate the molecular mechanisms linking ferroptosis to endothelial cell injury and vascular remodeling in PAH.

Main Methods:

• Analysis of ferroptosis-related gene expression using transcriptomic and single-cell RNA sequencing data from PAH patients.
• Induction of a PAH mouse model using combined hypoxia and Semaxanib (SU5416) treatment.
• Assessment of pulmonary vascular remodeling via right ventricular systolic pressure (RVSP), Fulton index, vascular wall thickness, and histology.

Main Results:

• Transcriptomic analysis revealed altered expression of key ferroptosis-related genes (SLC7A11, ACSL1, ACSL4) in PAH.
• Endothelial cells were identified as central players in ferroptosis-induced PAH.
• Inhibition of ferroptosis attenuated endothelial damage and pulmonary vascular remodeling in the PAH model.
• HIF1α signaling was found to be critical for ferroptosis induction in PAH.

Conclusions:

• Ferroptosis is a significant mechanism contributing to endothelial injury and pathogenesis in pulmonary arterial hypertension.
• Targeting ferroptosis presents a potential therapeutic strategy for early intervention and treatment of PAH.